1st anti-PVRIG/CD122R validated for multiplex IHC out now!

test our


CD112R antibody


The unique clone R12 is ideally suited for multiplexed IHC studies of CD112R expression in human tissue specimen.

TIGIT antibody


Clone TG1 has been validated on large quantities of tumor tissues and beta-tested by different labs for IHC-FFPE.

FOXP3 antibody


The new clone FX3 has been characterized on hundreds of tissues and validated for multiplex fluorescence IHC.


Clone TC8 displays highest signal-to-noise contrast and has been validated for detection of CD8+ TILs in multiplex assays.


Clone KK3 is highly efficient in detection of CD73-adenosine in normal and tumor FFPE tissue.


Coming soon – This clone has been validated on a high range of tissues to document unparalleled quality.

anti-PSA antibody


Clone HAM18 has been tested on >20.000 tissues and is the best characterized anti-PSA antibody.


Clone JAP16 is outstanding and superior to competitors as proven by beta-tests from different labs.

We are always happy to discuss your needs!



ONCOdianova is an antibody manufacturing network. The purpose is to manufacture excellent antibodies with optimized signal-to-noise ratio. Such optimized antibodies are especially needed in multicolor fluorescence based immunohistochemistry if many different antibodies are simultaneously analyzed. The mission of ONCOdianova is to develop a portfolio of “best in class antibodies” for proteins that are potentially relevant for triggering treatment decisions or for diagnostic pathology.


Our idea is to integrate immunohistochemistry as early as possible in the hybridoma screening procedure and thereby expand the classical ELISA screen by histopathological expertise at an early stage of FFPE antibody development.


We use our strong network for histopathological validation of new targets in human tissues. This expands our expertise to develop new test systems for novel targets. For cancer immunology targets we put a focus on tumor infiltrating lymphocytes.


Multiplex Assay technology develops fast and depends on the availability of reliable antibody reagents. Our vision is to provide the best cancer immunology marker antibodies for combined use to improve the understanding of patient subpopulations.


Our objective is to potentially develop multiple clones for the same target by approaching one target at diverse immunogenic sites. We are able to reference mapped epitopes and open for beta testing opportunities with pharmaceutical partners.